Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model

Terry H Landowski, Jaime Gard, Erika Pond, Gerald D. Pond, Raymond B Nagle, Christopher P. Geffre, Anne E Cress

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Laminin-binding integrin receptors are key mediators of epithelial cell migration and tumor metastasis. Recent studies have demonstrated a role for the α6 integrin (ITGA6/CD49f) in maintaining stem cell compartments within normal bone marrow and in residency of tumors metastatic to bone. In this study, we tested a function-blocking antibody specific for ITGA6, called J8H, to determine if preexisting cancer lesions in bone could be slowed and/or animal survival improved. Human prostate tumors were established by intracardiac injection into male SCID mice and treatment with J8H antibody was initiated after 1 week. Tumor progression was monitored by micro-computed tomography (CT) imaging of skeletal lesions. Animals that received weekly injections of the anti-ITGA6 antibody showed radiographic progression in only 40% of osseous tumors (femur or tibia), compared with control animals, where 80% of the lesions (femur or tibia) showed progression at 5 weeks. Kaplan-Meier survival analysis demonstrated a significant survival advantage for J8H-treated animals. Unexpectedly, CT image analysis revealed an increased proportion of bone lesions displaying a sclerotic rim of new bone formation, encapsulating the arrested lytic lesions in animals that received the anti-ITGA6 antibody treatment. Histopathology of the sclerotic lesions demonstrated wellcircumscribed tumor within bone, surrounded by fibrosis. These data suggest that systemic targeting of the ITGA6-dependent function of established tumors in bone may offer a noncytotoxic approach to arrest the osteolytic progression of metastatic prostate cancer, thereby providing anewtherapeutic strategy for advanced disease.

Original languageEnglish (US)
Pages (from-to)1558-1566
Number of pages9
JournalMolecular Cancer Therapeutics
Volume13
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Heterografts
Integrins
Neoplasm Metastasis
Bone and Bones
Neoplasms
Tibia
Femur
Anti-Idiotypic Antibodies
Tomography
Injections
Blocking Antibodies
SCID Mice
Kaplan-Meier Estimate
Laminin
Survival Analysis
Internship and Residency
Osteogenesis
Cell Movement
Prostate
Prostatic Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model. / Landowski, Terry H; Gard, Jaime; Pond, Erika; Pond, Gerald D.; Nagle, Raymond B; Geffre, Christopher P.; Cress, Anne E.

In: Molecular Cancer Therapeutics, Vol. 13, No. 6, 2014, p. 1558-1566.

Research output: Contribution to journalArticle

Landowski, Terry H ; Gard, Jaime ; Pond, Erika ; Pond, Gerald D. ; Nagle, Raymond B ; Geffre, Christopher P. ; Cress, Anne E. / Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model. In: Molecular Cancer Therapeutics. 2014 ; Vol. 13, No. 6. pp. 1558-1566.
@article{3d7d9817ad8842dda48ea133c31b50c0,
title = "Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model",
abstract = "Laminin-binding integrin receptors are key mediators of epithelial cell migration and tumor metastasis. Recent studies have demonstrated a role for the α6 integrin (ITGA6/CD49f) in maintaining stem cell compartments within normal bone marrow and in residency of tumors metastatic to bone. In this study, we tested a function-blocking antibody specific for ITGA6, called J8H, to determine if preexisting cancer lesions in bone could be slowed and/or animal survival improved. Human prostate tumors were established by intracardiac injection into male SCID mice and treatment with J8H antibody was initiated after 1 week. Tumor progression was monitored by micro-computed tomography (CT) imaging of skeletal lesions. Animals that received weekly injections of the anti-ITGA6 antibody showed radiographic progression in only 40{\%} of osseous tumors (femur or tibia), compared with control animals, where 80{\%} of the lesions (femur or tibia) showed progression at 5 weeks. Kaplan-Meier survival analysis demonstrated a significant survival advantage for J8H-treated animals. Unexpectedly, CT image analysis revealed an increased proportion of bone lesions displaying a sclerotic rim of new bone formation, encapsulating the arrested lytic lesions in animals that received the anti-ITGA6 antibody treatment. Histopathology of the sclerotic lesions demonstrated wellcircumscribed tumor within bone, surrounded by fibrosis. These data suggest that systemic targeting of the ITGA6-dependent function of established tumors in bone may offer a noncytotoxic approach to arrest the osteolytic progression of metastatic prostate cancer, thereby providing anewtherapeutic strategy for advanced disease.",
author = "Landowski, {Terry H} and Jaime Gard and Erika Pond and Pond, {Gerald D.} and Nagle, {Raymond B} and Geffre, {Christopher P.} and Cress, {Anne E}",
year = "2014",
doi = "10.1158/1535-7163.MCT-13-0962",
language = "English (US)",
volume = "13",
pages = "1558--1566",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model

AU - Landowski, Terry H

AU - Gard, Jaime

AU - Pond, Erika

AU - Pond, Gerald D.

AU - Nagle, Raymond B

AU - Geffre, Christopher P.

AU - Cress, Anne E

PY - 2014

Y1 - 2014

N2 - Laminin-binding integrin receptors are key mediators of epithelial cell migration and tumor metastasis. Recent studies have demonstrated a role for the α6 integrin (ITGA6/CD49f) in maintaining stem cell compartments within normal bone marrow and in residency of tumors metastatic to bone. In this study, we tested a function-blocking antibody specific for ITGA6, called J8H, to determine if preexisting cancer lesions in bone could be slowed and/or animal survival improved. Human prostate tumors were established by intracardiac injection into male SCID mice and treatment with J8H antibody was initiated after 1 week. Tumor progression was monitored by micro-computed tomography (CT) imaging of skeletal lesions. Animals that received weekly injections of the anti-ITGA6 antibody showed radiographic progression in only 40% of osseous tumors (femur or tibia), compared with control animals, where 80% of the lesions (femur or tibia) showed progression at 5 weeks. Kaplan-Meier survival analysis demonstrated a significant survival advantage for J8H-treated animals. Unexpectedly, CT image analysis revealed an increased proportion of bone lesions displaying a sclerotic rim of new bone formation, encapsulating the arrested lytic lesions in animals that received the anti-ITGA6 antibody treatment. Histopathology of the sclerotic lesions demonstrated wellcircumscribed tumor within bone, surrounded by fibrosis. These data suggest that systemic targeting of the ITGA6-dependent function of established tumors in bone may offer a noncytotoxic approach to arrest the osteolytic progression of metastatic prostate cancer, thereby providing anewtherapeutic strategy for advanced disease.

AB - Laminin-binding integrin receptors are key mediators of epithelial cell migration and tumor metastasis. Recent studies have demonstrated a role for the α6 integrin (ITGA6/CD49f) in maintaining stem cell compartments within normal bone marrow and in residency of tumors metastatic to bone. In this study, we tested a function-blocking antibody specific for ITGA6, called J8H, to determine if preexisting cancer lesions in bone could be slowed and/or animal survival improved. Human prostate tumors were established by intracardiac injection into male SCID mice and treatment with J8H antibody was initiated after 1 week. Tumor progression was monitored by micro-computed tomography (CT) imaging of skeletal lesions. Animals that received weekly injections of the anti-ITGA6 antibody showed radiographic progression in only 40% of osseous tumors (femur or tibia), compared with control animals, where 80% of the lesions (femur or tibia) showed progression at 5 weeks. Kaplan-Meier survival analysis demonstrated a significant survival advantage for J8H-treated animals. Unexpectedly, CT image analysis revealed an increased proportion of bone lesions displaying a sclerotic rim of new bone formation, encapsulating the arrested lytic lesions in animals that received the anti-ITGA6 antibody treatment. Histopathology of the sclerotic lesions demonstrated wellcircumscribed tumor within bone, surrounded by fibrosis. These data suggest that systemic targeting of the ITGA6-dependent function of established tumors in bone may offer a noncytotoxic approach to arrest the osteolytic progression of metastatic prostate cancer, thereby providing anewtherapeutic strategy for advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=84902650414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902650414&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-13-0962

DO - 10.1158/1535-7163.MCT-13-0962

M3 - Article

C2 - 24739392

AN - SCOPUS:84902650414

VL - 13

SP - 1558

EP - 1566

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -